Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294963" target="_blank" >RIV/00216208:11130/15:10294963 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/15:10294963

Result on the web

<a href="http://dx.doi.org/10.1080/2162402X.2015.1008866" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1008866</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2015.1008866" target="_blank" >10.1080/2162402X.2015.1008866</a>

Result language

angličtina

Original language name

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Original language description

The term "immunogenic cell death" (ICD) is now employed to indicate a functionally peculiar form of apoptosis that is sufficient for immunocompetent hosts to mount an adaptive immune response against dead cell-associated antigens. Several drugs have beenascribed with the ability to provoke ICD when employed as standalone therapeutic interventions. These include various chemotherapeutics routinely employed in the clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin) as well as some anticancer agents that are still under preclinical or clinical development (e.g., some microtubular inhibitors of the epothilone family). In addition, a few drugs are able to convert otherwise non-immunogenic instances of cell death into bona fide ICD, and may therefore be employed as chemotherapeutic adjuvants within combinatorial regimens. This is the case of cardiac glycosides, like digoxin and digitoxin, and zoledronic acid. Here, we dis

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EC - Immunology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

OncoImmunology [online]

ISSN

2162-402X

e-ISSN

—

Volume of the periodical

4

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

—

UT code for WoS article

000354224400025

EID of the result in the Scopus database

—